DBV Technologies Submitted BLA To U.S. FDA For Viaskin Peanut Patch In Children Aged 4-7 Years

By Reuters News

- DBV Technologies SA DBV.PA:

  • DBV TECHNOLOGIES ANNOUNCES SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO U.S. FDA FOR THE VIASKIN® PEANUT PATCH IN CHILDREN AGED 4-7 YEARS

  • HAS REQUESTED PRIORITY REVIEW OF BLA

  • BLA IS SUPPORTED BY THE RESULTS FROM THE SUCCESSFUL PHASE 3 VITESSE TRIAL

Source text: ID: nGNX7HTrs

Further company coverage: DBV.PA

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk